{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:52:36Z","timestamp":1781621556680,"version":"3.54.5"},"reference-count":27,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"6","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: Acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM) is characterized by an exaggerated inflammatory response and adverse myocardial remodeling. Sodium-glucose cotransporter-2 inhibitors (SGLT2-I) have demonstrated cardiometabolic benefits; however, their effects on circulating inflammatory biomarkers in diabetic AMI remain inconsistent. This meta-analysis aimed to quantitatively evaluate laboratory-based evidence regarding the modulation of key inflammatory markers by SGLT2-I therapy in this high-risk population. Methods: A systematic search of PubMed, ScienceDirect, Cochrane Library, Web of Science, CNKI, and Wanfang databases was conducted up to December 2025. Randomized controlled trials and prospective cohort studies involving T2DM patients with AMI were included. Primary laboratory endpoints were circulating inflammatory biomarkers (interleukin-6 [IL-6], high-sensitivity C-reactive protein [hs-CRP], tumor necrosis factor-a [TNF-a]). Secondary outcomes included left ventricular ejection fraction (LVEF) and major adverse cardiovascular events (MACE). Results: Thirteen studies comprising 2,453 patients were included. Meta-analysis demonstrated that, compared with the control group not receiving SGLT2 inhibitors, the observation group treated with SGLT2 inhibitors exhibited a significantly elevated level of LVEF (MD = 2.46, 95%CI: 1.04 to 3.87; P&amp;lt;0.001), as well as markedly reduced levels of IL-6 (MD=-2.33, 95%CI: -4.29 to -0.37; P&amp;lt;0.001) and hs-CRP)(MD=-1.90, 95%CI: -2.30 to -1.49; P&amp;lt;0.001), and a significantly lower risk of MACE (RR=0.47, 95%CI: 0.36 to 0.61; P&amp;lt;0.001). In addition, no significant reduction in TNF-a level was observed in the SGLT2-I group compared with the non-SGLT2-I group (MD = -2.66, 95% CI: -6.66 to 1.33; P = 0.19), potentially due to inter-study heterogeneity and limited sample size. Overall evidence quality was graded as moderate. Conclusion: This meta-analysis provides laboratory-based evidence that SGLT2 inhibitor therapy is associated with significant reductions in circulating IL-6 and hs-CRP levels in diabetic patients with AMI, supporting a potential anti-inflammatory mechanism beyond glucose lowering. These findings highlight the translational relevance of inflammatory biomarkers in evaluating cardiometabolic therapeutic strategies and underscore the need for larger mechanistic studies to further clarify biochemical pathways involved.<\/jats:p>","DOI":"10.5937\/jomb0-65034","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T12:01:16Z","timestamp":1774872076000},"page":"1207-1221","source":"Crossref","is-referenced-by-count":0,"title":["Modulation of circulating inflammatory biomarkers by SGLT2 inhibitors in diabetic patients with acute myocardial infarction: A quantitative meta-analysis of laboratory evidence"],"prefix":"10.5937","volume":"45","author":[{"given":"Jia","family":"Xu","sequence":"first","affiliation":[{"name":"Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Department of Pharmacy, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhong","family":"Jie","sequence":"additional","affiliation":[{"name":"Hospital of Jiangxi Provincial Armed Police Corps, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Dong","sequence":"additional","affiliation":[{"name":"Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Department of Pharmacy, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Department of Pathology, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Liu","sequence":"additional","affiliation":[{"name":"Huidong People's Hospital, Department of Endocrinology, Huizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","unstructured":"Krittanawong C, Khawaja M, Tamis-Holland JE, Girotra S, Rao SV Acute Myocardial Infarction: Etiologies and Mimickers in Young Patients. J Am Heart Assoc 2023; 12(18): e029971;"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Kufazvinei TTJ, Chai J, Boden KA, Channon KM, Choudhury RP Emerging opportunities to target inflam-mation: myocardial infarction and type 2 diabetes. Cardiovasc Res 2024; 120(11): 1241-52;","DOI":"10.1093\/cvr\/cvae142"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Kim YH, Her A, Rha S, Choi CU, Choi BG, Park S, et al. Impact of diabetes and ejection fraction on non-ST-Segment elevation myocardial infarction outcomes. Heart Vessels 2025; 40(11): 991-1004;","DOI":"10.1007\/s00380-025-02564-0"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Matter MA, Paneni F, Libby P Frantz S, Stahli BE, Templin C, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur Heart J 2024; 45(2): 89-103;","DOI":"10.1093\/eurheartj\/ehad486"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Yoo TT, Baek IH, Stoletniy L, Hilliard A, Sakr A, Doycheva D. Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review. Cardiovasc Diabetol 2025; 24(1): 227;","DOI":"10.1186\/s12933-025-02777-7"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Liu JF Qian XP Wang TX, Liu XL, Liu WG, Wang LJ, Zhang HF, Han L, Li GY, Yu XJ. Complement pathway: Risk molecular pattern of cardiovascular diseases in patients with diabetic nephropathy. J Med Biochem 2025; 44 (4): 801-7;","DOI":"10.5937\/jomb0-56221"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Preda A, Montecucco F, Carbone F Camici GG, L\u00fcscher TF Kraler S, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res 2024; 120(5): 443-60;","DOI":"10.1093\/cvr\/cvae047"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, et al. Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. Sci Rep-Uk 2022; 12(1): 15449;","DOI":"10.1038\/s41598-022-19371-6"},{"key":"ref9","unstructured":"Wang PZ, Cai TF, Tian J, Sang H, Li J, Tian P Zhang WQ. Effects of sacubitril valsartan sodium combined with dapagliflozin on cardiac function and left ventricular remodeling in patients with acute myocardial infarction and type 2 diabetes mellitus. Chinese Journal of Drug Application and Monitoring 2025; 22: 21-5;"},{"key":"ref10","unstructured":"Liu CC, Wang YB, Su LF, Zhou Q, Tian J, Hao GZ, Gu XS. Cardiorenal protective effect of dapagliflozin in patients with acute ST-segment elevation myocardial infarction and type 2 diabetes mellitus. Chinese Journal of Evidence-Based Cardiovascular Medicine 2025; 17: 1115-21;"},{"key":"ref11","unstructured":"Tang LL. Analysis of the Effects of Dagliflozin on Glucose Metabolism and Cardiac Function after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction and Diabetes Mellitus. Guide of China Medicine 2025; 23: 99-101;"},{"key":"ref12","unstructured":"Liu K, Chen YY, Chen HY, Xiang XJ, Qiao R, Nie P . Effects of dapagliflozin on glucose metabolism and cardiac function in patients with acute myocardial infarction complicated with diabetes mellitus after percutaneous coronary intervention. Northwest Pharmaceutical Journal 2024; 39: 189-93;"},{"key":"ref13","unstructured":"Lu YL, Xiao JD, Wang Y, Ma X. Influence of Dapagliflozin on glucose metabolism and cardiac function in elderly patients with ST-segment elevation myocardial infarction complicated with type 2 diabetes mellitus after percutaneous coronary intervention. Chinese Journal of Diabetes 2025; 33: 577-81;"},{"key":"ref14","unstructured":"Zhao L, Li Z. Effect of dapagliflozin intervention on ventricular remodeling and myocardial micro-perfusion in patients with acute myocardial infarction complicated with type 2 diabetes mellitus after percutaneous coronary intervention. Shaanxi Medical Journal 2022; 51: 81-3 + 95;"},{"key":"ref15","unstructured":"Lin W, Xiong SQ, Zhang P Zhao L, Li CY Lin C, Lin FY, Wang T. Clinical trial of daglizin in the treatment of patients with acute myocardial infarction complicated with type 2 diabetes. The Chinese Journal of Clinical Pharmacology 2024; 40: 2924-8;"},{"key":"ref16","unstructured":"Qi Y, Yin L, Li J, Zhao J, Wang HR, Xu JH. Effects of empagliflozin on ventricular remodeling and polarization of peripheral blood monocytes after interventional therapy for type 2 diabetes mellitus complicated with acute myocardial infarction. Northwest Pharmaceutical Journal 2025; 40: 165-70;"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Luo S, Liu H, Li Z, Zhou Y, He S, Zhang D, et al. Effects of SGLT2 Inhibitor in Patients with Diabetes with Newly Diagnosed Acute Myocardial Infarction: A Multicenter Prospective Cohort Study. Cardiovasc Drug Ther 2025: 10-1007;","DOI":"10.1007\/s10557-025-07716-y"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Heshmat A, Wakeel LME, Khorshid H, Fahmy SF Impact of dapagliflozin administration on remodeling marker and clinical outcomes of stemi patients with diabetes mellitus: a controlled clinical trial. Futur J Pharm Sci 2025; 11: 106;","DOI":"10.1186\/s43094-025-00864-w"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Lv Y, Luo W. Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes. World J Clin Cases 2024; 12(22): 5008-15;","DOI":"10.12998\/wjcc.v12.i22.5008"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Zhang L, Tang X, Li R, Niu J, Gong J. Efficacy of sacubitril\/valsartan combined with dapagliflozin in treating patients with heart failure and diabetes after an acute myocardial infarction. Pak J Med Sci 2024; 40(11): 2464-9;","DOI":"10.12669\/pjms.40.11.8972"},{"key":"ref21","unstructured":"Zhang TC, Bing CY, Li HT Effect of early application of canagliflozin on cardiac function and prognosis after percutaneous coronary intervention in patients with acute myocardial infarction and type 2 diabetes mellitus. Chinese Journal of Cardiovascular Research 2022; 20: 166-70;"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Profili NI, Castelli R, Manetti R, Sircana MC, Pagni M, Sechi GL, et al. Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction. Biomedicines 2025; 13(3): 720;","DOI":"10.3390\/biomedicines13030720"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Xia J, Li B, Zhang H, Li Q, Lam SM, Yin C, et al. Precise Metabolomics Defines Systemic Metabolic Dysregulation Distinct to Acute Myocardial Infarction Associated With Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology 2023; 43(4): 581-96;","DOI":"10.1161\/ATVBAHA.122.318871"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Yu Y, Que J, Liu S, Huang K, Qian L, Weng Y, et al. Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia\/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy. Front Cardiovasc Med 2022; 8: 768214;","DOI":"10.3389\/fcvm.2021.768214"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Xu X, Cai L, Chen T, Ding S, Zhang F , Gao B, et al. Predictive value of inflammation-based Glasgow prognostic score, platelet-lymphocyte ratio, and global registry of acute coronary events score for major cardiovascular and cerebrovascular events during hospitalization in patients with acute myocardial infarction. Aging 2021; 13(14): 18274-86;","DOI":"10.18632\/aging.203273"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Li Z, Li A, Sun D, Shu Y Effect of SGLT-2 Inhibitors on Prognosis in Diabetic Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med 2024; 25(5): 154;","DOI":"10.31083\/j.rcm2505154"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Paolisso P Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol 2022; 21(1): 77;","DOI":"10.1186\/s12933-022-01506-8"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Modulacija cirkuli\u0161u\u0107ih inflamatornih biomarkera inhibitorima SGLT2 kod dijabeti\u010dara sa akutnim infarktom miokarda - kvantitativna meta-analiza laboratorijskih dokaza"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/65034\/30505","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582606207X.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:04:20Z","timestamp":1781618660000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582606207X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-65034","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}